Korean pharmaceutical industry policy:Lessons for Korea
$5.40
SKU
9788968272905
[Free shipping over $100]
Standard Shipping estimated by Mon 05/12 - Fri 05/16 (주문일로부 10-14 영업일)
Express Shipping estimated by Wed 05/7 - Fri 05/9 (주문일로부 7-9 영업일)
* 안내되는 배송 완료 예상일은 유통사/배송사의 상황에 따라 예고 없이 변동될 수 있습니다.
| Publication Date | 2015/12/31 |
| Pages/Weight/Size | 160*235*20mm |
| ISBN | 9788968272905 |
| Categories | 사회 정치 > 사회비평/비판 |
Contents
Abstract 1
Chapter 1. Korean Pharmaceutical Industry and its policy 7
Session 1. Introduction 9
Session 2. Korea’s pharmaceutical industry today 12
Session 3. Direct investment in pharmaceutical R&D by the Korean
government 16
Session 4. Academic-industrial collaboration 20
Session 5. Insurance benefits and pricing 23
Session 6. Conclusion 26
Chapter 2. R&D Policy and Pharmaceutical Innovation 29
Session 1. Introduction 31
Session 2. Push and pull policies 33
Session 3. Government funding of R&D in pharmaceuticals 46
Session 4. Conclusion 59
Chapter 3. The Lessons for Korea Arising from the General
Regulation on Innovative Health Products 63
Session 1. Background 65
Session 2. DRG pricing 71
Session 3. Value based pricing 76
Session 4. Regulatory Impacts on R&D 93
Session 5. Potential Regulatory Solutions to Lengthening Time to
Market 101
Session 6. Conclusions 105
Reference 109
Chapter 1. Korean Pharmaceutical Industry and its policy 7
Session 1. Introduction 9
Session 2. Korea’s pharmaceutical industry today 12
Session 3. Direct investment in pharmaceutical R&D by the Korean
government 16
Session 4. Academic-industrial collaboration 20
Session 5. Insurance benefits and pricing 23
Session 6. Conclusion 26
Chapter 2. R&D Policy and Pharmaceutical Innovation 29
Session 1. Introduction 31
Session 2. Push and pull policies 33
Session 3. Government funding of R&D in pharmaceuticals 46
Session 4. Conclusion 59
Chapter 3. The Lessons for Korea Arising from the General
Regulation on Innovative Health Products 63
Session 1. Background 65
Session 2. DRG pricing 71
Session 3. Value based pricing 76
Session 4. Regulatory Impacts on R&D 93
Session 5. Potential Regulatory Solutions to Lengthening Time to
Market 101
Session 6. Conclusions 105
Reference 109